PDF(Pubmed)
Abstract：
UNASSIGNED: Hepatitis A is a widespread viral infection with significant public health implications. Assessing glucose 6-phosphate dehydrogenase (G6PD) deficiency in hepatitis A patients is essential for various reasons, including prognosis, disease severity evaluation, encephalopathy risk identification, tailored management, and advancing scientific understanding. This study aimed to investigate the prevalence and clinical implications of G6PD impairment in individuals with fulminant hepatitis A.
UNASSIGNED: A cross-sectional descriptive analysis was conducted, involving hospitalized patients with fulminant hepatitis A. Demographic data, prevalence rates, and clinical findings were recorded in a database. The diagnosis of hepatitis A infection was confirmed using an anti-HAV IgM antibody test, and G6PD enzyme activity was measured with a fluorescent spot assay.
UNASSIGNED: Out of 81 patients with hepatitis A, 57 (70.4%) were males, and 24 (29.5%) were females, with an average age of 24.6 years. Dark yellow urine and anorexia were the most common clinical symptoms. Notably, 30 (37%) patients lacked G6PD. The group with G6PD deficiency showed significantly higher rates of encephalopathy and mortality (P<0.01), along with elevated bilirubin (P=0.00), abnormal coagulation parameters, and low hemoglobin levels (P=0.00).
UNASSIGNED: In light of these findings, the present study proposes the implementation of routine G6PD level assessments and the evaluation of other relevant markers in regions where hepatitis A is endemic. Furthermore, the study underscores the need for vigilant monitoring of hemolysis and encephalopathy in affected patients to optimize clinical management and reduce morbidity and mortality associated with this condition.
UNASSIGNED: A cross-sectional descriptive analysis was conducted, involving hospitalized patients with fulminant hepatitis A. Demographic data, prevalence rates, and clinical findings were recorded in a database. The diagnosis of hepatitis A infection was confirmed using an anti-HAV IgM antibody test, and G6PD enzyme activity was measured with a fluorescent spot assay.
UNASSIGNED: Out of 81 patients with hepatitis A, 57 (70.4%) were males, and 24 (29.5%) were females, with an average age of 24.6 years. Dark yellow urine and anorexia were the most common clinical symptoms. Notably, 30 (37%) patients lacked G6PD. The group with G6PD deficiency showed significantly higher rates of encephalopathy and mortality (P<0.01), along with elevated bilirubin (P=0.00), abnormal coagulation parameters, and low hemoglobin levels (P=0.00).
UNASSIGNED: In light of these findings, the present study proposes the implementation of routine G6PD level assessments and the evaluation of other relevant markers in regions where hepatitis A is endemic. Furthermore, the study underscores the need for vigilant monitoring of hemolysis and encephalopathy in affected patients to optimize clinical management and reduce morbidity and mortality associated with this condition.
摘要：
甲型肝炎是一种具有重大公共卫生影响的广泛病毒感染。评估甲型肝炎患者的葡萄糖6-磷酸脱氢酶（G6PD）缺乏是必不可少的各种原因，包括预后，疾病严重程度评估，脑病风险识别，量身定制的管理，推进科学认识。本研究旨在调查暴发性甲型肝炎患者G6PD损害的患病率和临床意义。
■进行了横断面描述性分析，涉及重型甲型肝炎住院患者的人口统计数据，患病率，和临床发现记录在数据库中。使用抗HAVIgM抗体测试确认甲型肝炎感染的诊断，用荧光斑点测定法测定G6PD酶活性。
■在81名甲型肝炎患者中，57（70.4%）为男性，24名(29.5%)为女性，平均年龄为24.6岁。尿黄和厌食是最常见的临床症状。值得注意的是,30例（37%）患者缺乏G6PD。G6PD缺乏症组脑病发生率和病死率明显增高(P<0.01),胆红素升高（P=0.00），凝血参数异常，和低血红蛋白水平（P=0.00）。
■鉴于这些发现，本研究建议在甲型肝炎流行地区实施常规G6PD水平评估,并评估其他相关指标.此外，该研究强调需要对患病患者的溶血和脑病进行警惕监测,以优化临床管理并降低与该疾病相关的发病率和死亡率.
■进行了横断面描述性分析，涉及重型甲型肝炎住院患者的人口统计数据，患病率，和临床发现记录在数据库中。使用抗HAVIgM抗体测试确认甲型肝炎感染的诊断，用荧光斑点测定法测定G6PD酶活性。
■在81名甲型肝炎患者中，57（70.4%）为男性，24名(29.5%)为女性，平均年龄为24.6岁。尿黄和厌食是最常见的临床症状。值得注意的是,30例（37%）患者缺乏G6PD。G6PD缺乏症组脑病发生率和病死率明显增高(P<0.01),胆红素升高（P=0.00），凝血参数异常，和低血红蛋白水平（P=0.00）。
■鉴于这些发现，本研究建议在甲型肝炎流行地区实施常规G6PD水平评估,并评估其他相关指标.此外，该研究强调需要对患病患者的溶血和脑病进行警惕监测,以优化临床管理并降低与该疾病相关的发病率和死亡率.
